ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...

MILAN & MORRISTOWN, N.J., August 12, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies ...

It’s been a very busy few months since the Enigma team took home the Disrupt Cup back in New York, and co-founder Hicham Oudghiri took the stage here in San Francisco today to deliver an update on the ...

The issuer is solely responsible for the content of this announcement. Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with ...

The Independent Media Agencies of Australia (IMAA), the national industry body representing independent media agencies, has announced independent agency Enigma as the overall winner of its inaugural ...